Clin2
NCT06872658Possibly a fitNot yet recruiting

Retina immune cell study for dry AMD, MCI, or mild Alzheimer's

Dry Age Related Macular DegenerationMild Cognitive Impairment (MCI)Alzheimer Disease

Part of Brain & nervous system, Mental health clinical trials.

This study uses a special dye and imaging to see if certain immune cells (dendritic cells) travel to the retina. It aims to understand how the immune system might play a role in dry age-related macular degeneration, mild cognitive impairment due to Alzheimer's, or early Alzheimer's disease.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
15 people
Ages
55 years to 80 years
Study type
Observational

Who can take part

  • Age 55 to 80 years old.
  • In generally good health, with stable medications for at least one month.
  • For healthy volunteers: normal memory and thinking tests, no family history of Alzheimer's, no evidence of eye disease (other than needing glasses) or neurologic disease.
  • For dry AMD: advanced dry AMD with specific types of damage in the retina, vision better than 20/80, and not currently using injectable medications for AMD.
  • For MCI or mild Alzheimer's: mild memory or thinking problems, a positive Alzheimer's biomarker (like a blood test), and a study partner (family/friend) to attend visits.
  • No autoimmune diseases (like rheumatoid arthritis or lupus), no unstable heart or lung conditions, no recent drug or alcohol problems, and no use of certain immune-suppressing or antipsychotic medications.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03761381Recruiting
Eye scan study for mild Alzheimer’s and memory changes

This study uses detailed eye imaging (an eye scan) to look for signs related to probable Alzheimer’s disease and mild dementia. It may help researchers understand whether eye scans can reflect brain changes and improve detection.

Portland, Oregon
NCT06514001Recruiting· Phase 2
Testing a new drug for Alzheimer's disease with eye scans

This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.

Phoenix, Arizona
NCT05418231Not yet recruiting
Tracking vision changes in dry age-related macular degeneration

This study observes how dry age-related macular degeneration (AMD) changes over time using regular eye exams. It may help doctors better understand the natural pattern of progression and which patients are more likely to worsen.

Shanghai
NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests

This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.

Birmingham, Alabama
NCT04697095Recruiting
Testing immune cells from specific AMD eye types

This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.

Lyon
NCT07515521Recruiting
Vision and Imaging Tests for Early and Intermediate AMD

This study tests new ways to measure vision and take detailed eye images in people with age-related macular degeneration (AMD), a common eye condition affecting central vision. The goal is to develop better tools for future AMD treatment trials.

Bonn

Hear when a new Dry Age-related Macular Degeneration trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.